There are numerous factors to consider when assessing the safety of drugs in lactating women. Drug properties facilitating transfer into milk as well as the pharmacokinetic properties of the drug in the mother and infant must be evaluated. Drug properties which promote low milk concentrations are: large volume of distribution, high protein binding, low lipid solubility, ionization at physiologic pH and large molecular weight. Following transfer into breast milk, drugs with low bioavailability and short elimination half-lives in neonates have improved safety.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/089033449701300219 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Overview of Early-Life Gut Microbiota Modulation Strategies.
Ann Nutr Metab
January 2025
Department of Paediatrics, Medical University of Warsaw, Warsaw, Poland.
Background: The gut microbiota, or microbiome, is essential for human health. Early-life factors such as delivery mode, diet, and antibiotic use shape its composition, impacting both short- and long-term health outcomes. Dysbiosis, or alterations in the gut microbiota, is linked to conditions such as allergies, asthma, obesity, diabetes, inflammatory bowel disease, and necrotizing enterocolitis in preterm infants.
View Article and Find Full Text PDFMethod for Testing Drugs Belonging to Substrates and Inhibitors of the Transporter Protein BCRP on CACO-2 Cells.
Dokl Biochem Biophys
January 2025
Ryazan State Medical University, Ryazan, Russian Federation.
Introduction: Breast cancer resistance protein (BCRP) is an efflux membrane transporter that controls the pharmacokinetics of a large number of drugs. Its activity may change when taking some endo- and exogenous substances, thus making it a link in drug interactions.
Aim: The aim of the study was to develop a methodology for testing drugs for belonging to BCRP substrates and inhibitors in vitro.
Bioinspired complex cellulose nanorod-architectures: A model for dual-responsive smart carriers.
Carbohydr Polym
March 2025
Department of Chemistry, McGill University, 801 Sherbrooke Street West, Montreal, QC H3A 0B8, Canada; Quebec Centre for Advanced Materials (QCAM) and Pulp and Paper Research Centre, McGill University, 3420 University Street, Montreal, QC H3A 2A7, Canada. Electronic address:
The synergy between nanomaterials as solid supports and supramolecular concepts has resulted in nanomaterials with hierarchical structure and enhanced functionality. Herein, we developed and investigated innovative supramolecular functionalities arising from the synergy between organic moieties and the preexisting nanoscale soft material backbones. Based on these complex molecular nano-architectures, a new nanorod carbohydrate polymer carrier was designed with bifunctional hairy nanocellulose (BHNC) to reveal dual-responsive advanced drug delivery (ADD).
View Article and Find Full Text PDFBreast milk delivery of an engineered dimeric IgA protects neonates against rotavirus.
Mucosal Immunol
January 2025
Weill Cornell Medicine Department of Pediatrics, Division of Infectious Disease, New York, NY, USA. Electronic address:
Dimeric IgA (dIgA) is the dominant antibody in many mucosal tissues. It is actively transported onto mucosal surfaces as secretory IgA (sIgA) which plays an integral role in protection against enteric pathogens, particularly in young children. Therapeutic strategies that deliver engineered, potently neutralizing antibodies directly into the infant intestine through breast milk could provide enhanced antimicrobial protection for neonates.
View Article and Find Full Text PDFMFGE8 induces anti-PD-1 therapy resistance by promoting extracellular vesicle sorting of PD-L1.
Cell Rep Med
January 2025
Department of Orthopaedics of the Second Affiliated Hospital and Institute of Immunology, Zhejiang University School of Medicine, Hangzhou 310009, China. Electronic address:
Anti-PD-1 therapy, effective in patients with various advanced tumors, still encounters the challenge of insensitivity in most patients. Here, we demonstrate that PD-L1 on tumor cell-derived extracellular vesicles (TEVs) is critical for anti-PD-1 therapy resistance. Reducing endogenous and transferring exogenous TEVs abrogates and induces anti-PD-1 therapy resistance, respectively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!